GILD vs. MRNA, SGEN, TECH, AMGN, VRTX, REGN, BIIB, ALNY, BMRN, and NBIX
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Moderna (MRNA), Seagen (SGEN), Bio-Techne (TECH), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.
Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
Gilead Sciences received 2251 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Moderna currently has a consensus price target of $126.46, indicating a potential downside of 17.46%. Gilead Sciences has a consensus price target of $83.69, indicating a potential upside of 30.88%. Given Moderna's stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.
Moderna has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.
75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 15.2% of Moderna shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences has a net margin of 1.76% compared to Gilead Sciences' net margin of -115.82%. Moderna's return on equity of 24.34% beat Gilead Sciences' return on equity.
In the previous week, Moderna had 9 more articles in the media than Gilead Sciences. MarketBeat recorded 28 mentions for Moderna and 19 mentions for Gilead Sciences. Moderna's average media sentiment score of 0.79 beat Gilead Sciences' score of 0.49 indicating that Gilead Sciences is being referred to more favorably in the news media.
Summary
Gilead Sciences beats Moderna on 13 of the 17 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gilead Sciences Competitors List
Related Companies and Tools
